First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients
A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours
Sponsor: Molecular Partners AG
A PHASE1/PHASE2 clinical study on Neoplasms, this trial is completed. The trial is conducted by Molecular Partners AG and has accumulated 9 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2018 — May 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Molecular Partners AG
For direct contact, visit the study record on ClinicalTrials.gov .